Immutep rises on plans to expand cancer drug trial

Immutep

30/03/2023 17:42

** U.S.-listed shares of Australia-based Immutep Ltd
 IMMP.O  rise 3.6% to $1.72 
    ** Drug developer says it has signed an agreement to expand
the trial population in the ongoing early-stage study testing
its experimental triple combination therapy to treat a type of
lung cancer     
    ** Says the trial which had an enrolment target of 20
patients will now be expanded to 50 patients across multiple
sites- IMMP
    ** Expansion based on strong initial efficacy and safety
results -IMMP
    ** The trial evaluates co's drug candidate, eftilagimod
alpha, with standard-of-care combination of anti-PD-1 therapy
and chemotherapy to treat first-line non- small cell lung cancer
-IMMP     
    ** Stock down ~32% in the past 12 months

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))